News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Merck & Co., Inc. (MRK)’s Proscar Fails to Win U.S. FDA Panel’s Backing for Prostate Cancer


12/2/2010 6:28:41 AM

Bloomberg -- Merck & Co.’s enlarged-prostate treatment Proscar failed to win the support of a U.S. advisory panel for use in preventing prostate cancer. Outside advisers to the Food and Drug Administration voted 17-0 with one abstention today that Proscar has an unfavorable balance of risks and benefits in healthy men at least 55 years old. Merck, based in Whitehouse Station, New Jersey, asked to add data from its studies in prostate cancer to the prescribing information for Proscar, approved in 1992.

Read at Bloomberg
Read at BusinessWeek
Read at MedPageToday


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES